Back to Search Start Over

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

Authors :
Yuriko Nishiyama-Fujita
Tomonori Nakazato
Noriyoshi Iriyama
Michihide Tokuhira
Maho Ishikawa
Eriko Sato
Tomoiku Takaku
Keiji Sugimoto
Hiroyuki Fujita
Isao Fujioka
Shun Tsuchiya
Yuta Kimura
Eisaku Iwanaga
Norio Komatsu
Norio Asou
Masahiro Kizaki
Yoshihiro Hatta
Tatsuya Kawaguchi
Source :
Annals of Medicine. 54:1244-1254
Publication Year :
2022
Publisher :
Informa UK Limited, 2022.

Abstract

Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs). We retrospectively analysed the clinical features, treatment response, and long-term outcomes of 42 AYA patients, in comparison to older patients. The initial therapies of AYA patients between 2001 and 2016 included imatinib (n = 24), dasatinib (n = 13) and nilotinib (n = 5). In AYA patients, the peripheral blood (PB) white blood cell count and percentage of blasts at the diagnosis were significantly higher, haemoglobin levels were lower and the spleen size was larger. The major molecular response (MMR), event-free survival (EFS) and overall survival (OS) rates were comparable. A sub-analysis comparing imatinib to second-generation TKIs as the initial therapy also showed that their prognosis was comparable. In conclusion, the tumour burden at the diagnosis of CML-CP is higher in AYA patients; however, their prognosis was not worse in comparison to older patients treated with TKIs. KEY MESSAGESFew studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs). This study showed the tumour burden at the diagnosis of CML-CP is higher in AYA pa tients; however, their prognosis was not worse in comparison to older patients treated with TKIs. Understanding the biological and non-biological features of AYA patients with CML-CP on TKI therapy is essential for better management and to improve the outcomes. Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs). This study showed the tumour burden at the diagnosis of CML-CP is higher in AYA pa tients; however, their prognosis was not worse in comparison to older patients treated with TKIs. Understanding the biological and non-biological features of AYA patients with CML-CP on TKI therapy is essential for better management and to improve the outcomes.

Details

ISSN :
13652060 and 07853890
Volume :
54
Database :
OpenAIRE
Journal :
Annals of Medicine
Accession number :
edsair.doi.dedup.....69f16f6a446caa1148dc5d0cc04c9622
Full Text :
https://doi.org/10.1080/07853890.2022.2069280